Search Results
Mar 24, 2026, 14:00 ET Myosin Therapeutics Awarded Florida Cancer Innovation Fund Grant to Support STAR-GBM Clinical Trial
TherapeuticsMyosin Therapeutics is a biotechnology company based in Jupiter, Florida, developing first-in-class therapies for oncology and CNS disorders by targeting molecular nanomotor proteins. The company's lead program, MT-125, is being developed for the treatment of multiple aggressive
More news about: Myosin Therapeutics Inc.
Mar 24, 2026, 13:49 ET American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education
the science of nutrition and translating that science into meaningful action for patients and healthcare professionals alike," said Corinne Bush, MS, CNS, CEO of the American Nutrition Association. "At ANA, the first of our core values is that nutrition is a science. Excess sodium intake is one of the
More news about: American Nutrition Association
Mar 24, 2026, 09:17 ET Belay Diagnostics Reports 82% Clinical Impact Rate for Summit™ and Vantage™ in CNS Lymphoma Study
this cohort were MYD88, a hallmark of CNS lymphoma, followed by TP53 and CD79B, demonstrating that Summit can identify alterations critical to CNS lymphoma diagnosis. Aneuploidy findings were also clinically significant: several cases with concern for metastatic CNS lymphoma showed five or more aneuploidy
More news about: Belay Diagnostics
Mar 24, 2026, 09:00 ET RGNX Shareholder Alert: April 14, 2026 Lead Plaintiff Deadline in REGENXBIO Inc. Securities Class Action Lawsuit -- The Gross Law Firm
press release announcing that the FDA placed a clinical hold on its investigational gene therapy RGX-111. Defendants announced that an intraventricular CNS tumor was found in a participant treated in its RGX-111 Phase I/II study. Following this news, the price of REGENXBIO's common stock declined from a
More news about: The Gross Law Firm
Mar 24, 2026, 07:00 ET Corero Network Security Wins Two Global InfoSec Awards, Including Publisher's Choice for Cyber Resilience
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), leader in real-time DDoS protection and service availability, today announced it has received two Global InfoSec Awards from Cyber Defense
More news about: Corero Network Security
Mar 24, 2026, 07:00 ET Corero Network Security Accelerates ARR Growth 23% as Demand for Real-Time Protection Surges
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), leader in real-time DDoS protection and service availability, today announced its audited results for the year ended 31 December 2025,
More news about: Corero Network Security
Mar 24, 2026, 02:25 ET Manipal Hospital Kanakapura Road Celebrates Women Who Shape Communities with Courage and Compassion
Hariharan, Cluster Director - Manipal Hospital Kanakapura Road and Jayanagar, Dr. Bhavana B, Marketing Head - Regional South, Manipal Hospitals, Ms. Rose, CNS - Manipal Hospital Kanakapura Road, along with doctors including Dr. Sowmya M, Senior Consultant - Neurology, Dr. Anjana Ravindranath, Consultant - Emergency
More news about: Manipal Hospitals
Mar 23, 2026, 10:01 ET Animal Drug Compounding Market to Reach US$ 2.3 Billion by 2033, Expands Amid Rising Pet Healthcare Demand and Personalized Veterinary Medicine - Persistence Market Research
products, including compounded medications, through more integrated supply chains.Segmentation Insights: CNS Agents Lead While Anti-Infectives Accelerate Rapid GrowthCNS (Central Nervous System) agents dominate the global animal drug compounding market, accounting for around 33% of
More news about: Persistence Market Research Pvt. Ltd.
Mar 23, 2026, 09:04 ET 28bio's Endurance Study Meets Primary Endpoint, Showing CNS-3D Brain Organoids Predict Clinical Seizure Liability
CNS-3D Brain Organoids in small molecules with documented human clinical outcomes from 120,551 patients and known positive controls. The study focuses on seizure liability, one of the most challenging and regulatory-critical CNS adverse effects to predict in neurological
More news about: 28bio
Mar 23, 2026, 08:00 ET Sumitomo Pharma America Announces that its Investigational Therapy DSP-3077 Has Received FDA Orphan Drug Designation for the Treatment of Retinitis Pigmentosa
(Sumitomo Pharma Canada, Inc.) focused on addressing patient needs in oncology, urology, women's health, rare diseases, cell & gene therapies and CNS. With several marketed products in the U.S., Canada, and Europe, a diverse pipeline of early- to late-stage assets, we aim to accelerate discovery, research,
More news about: Sumitomo Pharma America
Mar 23, 2026, 02:29 ET Monash University and ClinChoice Forge Strategic Partnership to Accelerate Clinical Development of Innovative Therapies
Indo/Asia-Pacific, ClinChoice brings deep therapeutic expertise in hematology/oncology, immunology and inflammation (I&I), cardiometabolics and CNS. Having delivered more than 3,000 studies globally, ClinChoice has a strong track record of working with biopharmaceutical companies worldwide, and delivering
More news about: ClinChoice Inc
Mar 23, 2026, 02:10 ET Monash University and ClinChoice Forge Strategic Partnership to Accelerate Clinical Development of Innovative Therapies
Indo/Asia-Pacific, ClinChoice brings deep therapeutic expertise in hematology/oncology, immunology and inflammation (I&I), cardiometabolics and CNS. Having delivered more than 3,000 studies globally, ClinChoice has a strong track record of working with biopharmaceutical companies worldwide, and delivering
More news about: ClinChoice Inc
Mar 22, 2026, 09:28 ET RGNX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular CNS tumor) in a participant treated in its Phase I/II study." The press release also disclosed that "[t]he FDA also placed a clinical hold on RGX-121, for
More news about: Faruqi & Faruqi, LLP
Mar 21, 2026, 13:28 ET TTW Reveals Top 50 Safest Travel Destinations Around the World for 2026
wildlife experiences.Fly into Cairns Airport (CNS) or Hamilton Island Airport, then take boat tours.4
More news about: Travel And Tour World
Mar 19, 2026, 21:00 ET D3 Bio to Showcase Its Innovative KRAS Pipeline at AACR 2026, Including an Oral Presentation at Clinical Plenary Session
cycling and suppressing oncogenic signaling. Preclinical studies show robust potency, complete KRAS G12C engagement at clinically relevant exposures, and CNS penetration capability. Elisrasib‑ is currently being evaluated globally in a Phase 2 monotherapy and combination trial across KRAS G12C–mutant solid
More news about: D3 Bio
Mar 19, 2026, 16:00 ET Curis Provides Fourth Quarter 2025 Business Update
HighlightsTakeAim LymphomaLakshmi Nayak, MD, Director of the Center for CNS Lymphoma at Dana-Farber Cancer Institute in Boston, presented a poster with updated clinical data in Primary CNS Lymphoma (PCNSL) at the 30th Annual Meeting of the Society for Neuro-Oncology (SNO)
More news about: Curis, Inc.
Mar 19, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX
therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular CNS tumor) in a participant treated in its Phase I/II study." The press release also disclosed that "[t]he FDA also placed a clinical hold on RGX-121, for
More news about: Pomerantz LLP
Mar 19, 2026, 09:57 ET Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model
Lunai BioworksLunai Bioworks (NASDAQ: LNAI) is an AI-enabled biotechnology company advancing rapid in vivo phenotypic drug discovery across CNS and biodefense applications. By integrating high-throughput vertebrate screening with machine learning analytics, Lunai seeks to accelerate therapeutic
More news about: Lunai Bioworks Inc.
Mar 19, 2026, 09:00 ET STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: SUEWALLST, LLP
made a series of statements emphasizing that RGX-111 was "well-tolerated" with "no drug-related serious adverse events" and highlighting "encouraging CNS biomarker activity." These statements spanned multiple disclosure events:- February 9, 2022: Announced "no drug-related serious adverse events"
More news about: SueWallSt.com
Mar 19, 2026, 09:00 ET ImmunoBrain Presents Clinical Data for First Immune Checkpoint Therapy Approach in Alzheimer's Disease at AD/PD™ 2026
the Netherlands, and Israel. The primary and secondary endpoints of the study were safety, tolerability, and pharmacokinetics. Exploratory measures of CNS engagement included AD-related CSF biomarkers at 12 months. All immune-related adverse events were generally mild and manageable, with no serious adverse
More news about: ImmunoBrain Checkpoint Inc.
Mar 19, 2026, 08:10 ET Ractigen Therapeutics Announces China NMPA IND Approval for Phase II Clinical Trial of saRNA Therapy RAG-01 in Non-Muscle Invasive Bladder Cancer
development of RNA-based solutions, including siRNAs, where applicable, to target life-threatening, fast-progressing conditions such as those in the CNS. Committed to scientific excellence and patient-centered innovation, Ractigen strives to transform healthcare through the power of RNA therapeutics.
More news about: Ractigen Therapeutics
Mar 18, 2026, 09:55 ET STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: LEVI & KORSINSKY, LLP
made a series of statements emphasizing that RGX-111 was "well-tolerated" with "no drug-related serious adverse events" and highlighting "encouraging CNS biomarker activity." These statements spanned multiple disclosure events:February 9, 2022: Announced "no drug-related serious
More news about: Levi & Korsinsky, LLP
Mar 17, 2026, 17:15 ET Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026
for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and to avoid inhibition of the structurally related tropomyosin receptor kinase (TRK) family. Together, these characteristics have the potential to avoid TRK-related CNS adverse events seen with
More news about: Nuvalent, Inc.
Mar 17, 2026, 16:46 ET Brenig Therapeutics Announces Oral Presentation of Phase 1 Data for BT-267 at AD/PD™ 2026, and Provides Updates on BT-409, its NLRP3 Inhibitor Program
underway.The presentation will highlight emerging clinical data evaluating the safety, tolerability, pharmacokinetics (PK), and central nervous system (CNS) penetration of BT-267 in healthy volunteers.Presentation DetailsTitle: Phase 1 Study of BT-267, a potent, selective, brain-penetrant,
More news about: Brenig Therapeutics Inc
Mar 17, 2026, 16:35 ET Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026
of disease progression, with about 50% of previously treated patients developing central nervous system (CNS) metastases.About IBTROZIIBTROZI is an oral, potent, CNS-active, selective, next-generation ROS1 inhibitor therapy. On June 11, 2025, following Priority Review and Breakthrough
More news about: Nuvation Bio Inc.